Effect of Inflammatory Bowel Disease (IBD) and IBD Medications on Dyslipidemia Risk

Background: Inflammatory bowel diseases (IBDs), including Crohn's disease (CD) and ulcerative colitis (UC), involve chronic intestinal inflammation and are associated with increased risks of clotting abnormalities, venous thromboembolism (VTE), cardiovascular diseases, and vascular complications, necessitating regular monitoring of lipid profiles to manage treatment and prevent complications.
Objectives: This study aimed to evaluate lipid profiles in patients newly diagnosed with ulcerative colitis (UC) and crohn’s disease (CD) and follow up their lipid profiles after 4 months and 8 months from the diagnosis and start of treatment.
Subjects and methods: This prospective study was performed on 80 Egyptian IBD patients who were newly diagnosed and followed up their lipid profiles in outpatient clinics gastroenterology department at Ain Shams University hospitals. The patients were selected from The Department of Gastroenterology and Gastroenterology Outpatient Clinic through the period from January 2024 till December 2024.
Result: There was high statistically significant difference between lipid profile in different periods in CD and UC cases. Among the studied cases with IBD, CD was the dominating disease in 50 (62.5%) of the cases, the most common diagnosis was Ileocolonic in 18 (22.5%) of cases.
Conclusion: IBD and its medications can significantly impact the risk of hyperlipidemia. Chronic inflammation in IBD can disrupt lipid metabolism, leading to changes in cholesterol and triglyceride levels, increasing the risk of cardiovascular diseases.